{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:06:44Z","timestamp":1787069204144,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1124\/dmd.115.064790","type":"journal-article","created":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T21:23:51Z","timestamp":1441142631000},"page":"1806-1814","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["In Vitro Characterization of the Human Liver Microsomal Kinetics and Reaction Phenotyping of Olanzapine Metabolism"],"prefix":"10.1016","volume":"43","author":[{"given":"Porntipa","family":"Korprasertthaworn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Polasek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Sorich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"McLachlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John O.","family":"Miners","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey T.","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Rowland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.115.064790_bib1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1046\/j.1365-2125.1999.00030.x","article-title":"Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone","volume":"48","author":"Baldwin","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.115.064790_bib2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1055\/s-2004-832687","article-title":"The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry","volume":"37","author":"Baumann","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"10.1124\/dmd.115.064790_bib3","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1046\/j.1365-2125.2002.01669.x","article-title":"In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine","volume":"54","author":"Boase","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.115.064790_bib4","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2125.2005.02446.x","article-title":"S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen","volume":"60","author":"Bowalgaha","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.115.064790_bib5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/00498250310001636868","article-title":"Optimizing bacterial expression of catalytically active human cytochromes P450: comparison of CYP2C8 and CYP2C9","volume":"34","author":"Boye","year":"2004","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.115.064790_bib7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00004714-200304000-00003","article-title":"Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine","volume":"23","author":"Carrillo","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"10.1124\/dmd.115.064790_bib8","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2174\/187231208784040942","article-title":"Analysis of flavin-containing monooxygenase 3 genotype data in populations administered the anti-schizophrenia agent olanzapine","volume":"2","author":"Cashman","year":"2008","journal-title":"Drug Metab Lett"},{"key":"10.1124\/dmd.115.064790_bib9","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3109\/00498254.2011.618954","article-title":"Quantitative distribution of mRNAs encoding the 19 human UDP-glucuronosyltransferase enzymes in 26 adult and 3 fetal tissues","volume":"42","author":"Court","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.115.064790_bib10","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/FPC.0b013e328348c76b","article-title":"Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants","volume":"21","author":"Erickson-Ridout","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.115.064790_bib11","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00228-009-0783-8","article-title":"Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure--an impact similar to male gender or smoking in schizophrenic patients","volume":"66","author":"Ghotbi","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.115.064790_bib12","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s002280100343","article-title":"Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes","volume":"57","author":"H\u00e4gg","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.115.064790_bib13","first-page":"848","article-title":"Olanzapine 10-N-glucuronide. A tertiary N-glucuronide unique to humans","volume":"26","author":"Kassahun","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.064790_bib14","first-page":"81","article-title":"Disposition and biotransformation of the antipsychotic agent olanzapine in humans","volume":"25","author":"Kassahun","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.064790_bib15","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1124\/dmd.113.051565","article-title":"Human UDP-glucuronosyltransferase (UGT) 2B10 in drug N-glucuronidation: substrate screening and comparison with UGT1A3 and UGT1A4","volume":"41","author":"Kato","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.064790_bib16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/tpj.2009.32","article-title":"Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome","volume":"10","author":"Laika","year":"2010","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/dmd.115.064790_bib17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hup.403","article-title":"Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes","volume":"17","author":"Linnet","year":"2002","journal-title":"Hum Psychopharmacol"},{"key":"10.1124\/dmd.115.064790_bib18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00003088-200746050-00001","article-title":"Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response","volume":"46","author":"Mauri","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.115.064790_bib19","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1046\/j.1365-2125.2000.00193.x","article-title":"Nonspecific binding of drugs to human liver microsomes","volume":"49","author":"McLure","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.115.064790_bib20","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0163-7258(91)90065-T","article-title":"Drug glucuronidation in humans","volume":"51","author":"Miners","year":"1991","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.115.064790_bib21","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1124\/dmd.109.031542","article-title":"Human liver expression of CYP2C8: gender, age, and genotype effects","volume":"38","author":"Naraharisetti","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.064790_bib22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/FTD.0b013e31816336fd","article-title":"The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP)","volume":"30","author":"Nozawa","year":"2008","journal-title":"Ther Drug Monit"},{"key":"10.1124\/dmd.115.064790_bib23","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00004714-200102000-00004","article-title":"Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial","volume":"21","author":"Perry","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"10.1124\/dmd.115.064790_bib24","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0022-3565(25)12326-4","article-title":"Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine","volume":"276","author":"Ring","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.115.064790_bib25","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1001\/jama.290.20.2693","article-title":"Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial","volume":"290","author":"Rosenheck","year":"2003","journal-title":"JAMA"},{"key":"10.1124\/dmd.115.064790_bib26","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1124\/dmd.107.019885","article-title":"The \u201calbumin effect\u201d and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9","volume":"36","author":"Rowland","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.064790_bib27","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/dmd.106.009340","article-title":"In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction","volume":"34","author":"Rowland","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.064790_bib28","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1124\/jpet.106.118216","article-title":"Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation","volume":"321","author":"Rowland","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.115.064790_bib29","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1124\/dmd.108.021105","article-title":"The \u201calbumin effect\u201d and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities","volume":"36","author":"Rowland","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.064790_bib43","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.biocel.2013.02.019","article-title":"The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification","volume":"45","author":"Rowland","year":"2013","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1124\/dmd.115.064790_bib30","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2165\/11587240-000000000-00000","article-title":"Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia?","volume":"50","author":"Schwenger","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.115.064790_bib31","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/sj.npp.1300123","article-title":"Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers","volume":"28","author":"Shirley","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/dmd.115.064790_bib32","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/JCP.0b013e318204d9e2","article-title":"High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug","volume":"31","author":"Skogh","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"10.1124\/dmd.115.064790_bib33","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/FPC.0b013e3283602876","article-title":"Influence of CYP1A1\/CYP1A2 and AHR polymorphisms on systemic olanzapine exposure","volume":"23","author":"S\u00f6derberg","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.115.064790_bib34","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/tpj.2012.47","article-title":"Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients","volume":"13","author":"S\u00f6derberg","year":"2013","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/dmd.115.064790_bib35","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0022-3565(25)12102-2","article-title":"Variability in human cytochrome P450 paclitaxel metabolism","volume":"275","author":"Sonnichsen","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.115.064790_bib36","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.clpt.2004.12.267","article-title":"Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance","volume":"77","author":"Totah","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.115.064790_bib37","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.bcp.2003.08.025","article-title":"Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7","volume":"67","author":"Tsoutsikos","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.115.064790_bib38","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1124\/dmd.32.4.413","article-title":"Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid","volume":"32","author":"Uchaipichat","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.064790_bib39","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00228-011-1001-z","article-title":"In vitro-in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6\u03b1-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance","volume":"67","author":"Wattanachai","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.115.064790_bib40","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1124\/dmd.111.044057","article-title":"Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: impact on in vitro-in vivo extrapolation of drug clearance","volume":"40","author":"Wattanachai","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.064790_bib41","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1016\/j.lfs.2006.08.016","article-title":"The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes","volume":"79","author":"Yao","year":"2006","journal-title":"Life Sci"},{"key":"10.1124\/dmd.115.064790_bib42","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Ther"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624102280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624102280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.115.064790","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T14:25:09Z","timestamp":1739888709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624102280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0090955624102280"],"URL":"https:\/\/doi.org\/10.1124\/dmd.115.064790","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In Vitro Characterization of the Human Liver Microsomal Kinetics and Reaction Phenotyping of Olanzapine Metabolism","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.115.064790","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}